[Inflammatory injurious effect of angiotensin II on pulmonary microvascular endothelium in rat]

Hong Zhang1, Geng-Yun Sun

  • 1Department of Emergency, First Affiliated Hospital, Anhui Medical University, Hefei 230061, Anhui, China.

Abstract

Insights

Angiotensin II (AngII) worsens lung microvascular endothelial cell injury caused by lipopolysaccharide (LPS). Blocking the Angiotensin II type 1 receptor prevents this combined damage, suggesting a therapeutic target.

Area of Science:

  • Pulmonary vascular research
  • Endothelial cell biology
  • Cardiovascular pharmacology

Context:

  • Pulmonary microvascular endothelial cells (RPMVECs) form a critical barrier in the lungs.
  • Endothelial barrier dysfunction is implicated in acute lung injury.
  • Angiotensin II (AngII) plays a role in vascular regulation and inflammation.

Purpose:

  • To investigate the synergistic effects of AngII and lipopolysaccharide (LPS) on RPMVEC monolayer permeability.
  • To determine if blocking the Angiotensin II type 1 receptor can prevent AngII and LPS-induced endothelial injury.

Summary:

  • Lipopolysaccharide (LPS) significantly increased RPMVEC monolayer permeability.
  • Angiotensin II (AngII) exacerbated LPS-induced permeability, indicating a synergistic injurious effect.
  • (Sar1, Ile8)-Ang II, an Angiotensin II type 1 receptor antagonist, significantly prevented this synergistic damage.

Impact:

  • This study highlights the detrimental interaction between AngII and LPS in the pulmonary endothelium.
  • Targeting the Angiotensin II type 1 receptor may offer a therapeutic strategy to mitigate LPS-induced lung injury.
  • Findings contribute to understanding endothelial dysfunction in critical care settings.